A Study of Lenalidomide for Adult Histiocyte Disorders
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for
one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester
disease (ECD), or histiocytic sarcoma (HS).